Pharmacokinetics/Pharmacodynamics of Albiglutide

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 283 participants.

Also called NCT01357889

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 283 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01357889
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01357889. Randomized; double masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-10 (actual). Results posted on 2014-05-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacokinetics/Pharmacodynamics of Albiglutide
Condition
Diabetes Mellitus, Type 2
Intervention (Biological)
albiglutide (GSK716155)
Intervention (Biological)
albiglutide (GSK716155)
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01357889
Content hash
385e43a27653deff279b17f6f80b07f514f3294613b3ba00de61f14081b19997